Wyniki wyszukiwania

1

Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik

Design, molecular docking, drug-likeness, and molecular dynamics studies of 1,2,4-trioxane derivatives as novel Plasmodium falciparum falcipain-2 (FP-2) inhibitors

100%

Ghosh S., Chetia D., Gogoi N., Rudrapal M.

BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology

|

2021

|

tom 102

|

nr 3

2

The efficacy of combination therapy with lenalidomide and dexamethasone in the treatment of relapsed multiple myeloma

84%

Szudy-Szczyrek A., Legiec W., Manko J., Gmyz K., Szczyrek M., Hus M.

Health Problems of Civilization

|

2015

|

tom 09

|

nr 2

Multiple myeloma is a neoplastic disease which is characterised by proliferation of monoclonal plasmocytes in the bone marrow. It is the second most common hematologic cancer and it represents 1% of all cancer deaths. Despite enormous development in multiple myeloma biology and treatment over the last 30 years - it is still incurable disease with a median survival of 50 – 55 months. Currently, one of the most important goals in the treatment of multiple myeloma is to achieve long-term control of the disease, without negative impact on the patient’s quality of life. Thanks to therapeutic regimens based on new immunomodulatory drugs, this aim seems to be achievable. In this paper we present the case of a female patient living with multiple myeloma for 14 years. Initially patient was treated with standard VAD (vincristine, doxorubicin, dexamethasone) chemotherapy regimen. After a nearly complete remission of the disease, autotransplantation of hematopoietic cells was performed. One year after transplantation there was a relapse of the disease. In the treatment of relapse it was decided to use scheme based on lenalidomide and dexamethasone. After 4th cycle of treatment, a complete remission was achieved. So far, the patient received 149 cycles. In the evaluation of minimal residual disease still maintains a state of complete remission maintains. During over 12 years of treatment no complications in grade 3 and 4 of the CTCAE v.4 was observed. Currently the patient is 58 years old, she still receives lenalidomide and leads moderately active life.

3

A recently developed approach in tumor therapy using Salmonella

84%

Gharbavi M., Karimkhanlooei G., Amani J., Kashiazari P., Sharafi A.

BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology

|

2020

|

tom 101

|

nr 3

4

Combination of vasostatin and cyclophosphamide in the therapy of murine melanoma tumors

84%

Jazowiecka-Rakus J., Jarosz M., Kozlowska D., Sochanik A., Szala S.

Acta Biochimica Polonica

|

2007

|

tom 54

|

nr 1

Growth of tumors is strongly dependent upon supply of nutrients and oxygen by de novo formed blood vessels. Inhibiting angiogenesis suppresses growth of primary tumors as well and affects development of metastases. We demonstrate that recombinant MBP/vasostatin fusion protein inhibits proliferation of endothelial cells in vitro. The therapeutic usefulness of such intratumorally delivered recombinant protein was then assessed by investigating its ability to inhibit growth of experimental murine melanomas. In the model of B16-F10 melanoma the MBP/vasostatin construct significantly delayed tumor growth and prolonged survival of treated mice. A combination therapy involving MBP/vasostatin construct and cyclophosphamide was even more effective and led to further inhibition of the tumor growth and extended survival. We show that such combination might be useful in the clinical setting, especially to treat tumors which have already formed microvessel networks.

5

A practical algorithm management of patients with benign prostatic hyperplasia

67%

Dutkiewicz S.

Journal of Pre-Clinical and Clinical Research

|

2008

|

tom 02

|

nr 2

Ograniczanie wyników

2 BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology

1 Acta Biochimica Polonica

1 Health Problems of Civilization

1 Journal of Pre-Clinical and Clinical Research

1 Amani J.

1 Chetia D.

1 Dutkiewicz S.

1 Gharbavi M.

1 Ghosh S.

1 Gmyz K.

1 Gogoi N.

1 Hus M.

1 Jarosz M.

1 Jazowiecka-Rakus J.

1 Karimkhanlooei G.

1 Kashiazari P.

1 Kozlowska D.

1 Legiec W.

1 Manko J.

1 Rudrapal M.

1 Sharafi A.

1 Sochanik A.

1 Szala S.

1 Szczyrek M.

1 Szudy-Szczyrek A.

1 2021

1 2020

1 2015

1 2008

1 2007

Design, molecular docking, drug-likeness, and molecular dynamics studies of 1,2,4-trioxane derivatives as novel Plasmodium falciparum falcipain-2 (FP-2) inhibitors

The efficacy of combination therapy with lenalidomide and dexamethasone in the treatment of relapsed multiple myeloma

A recently developed approach in tumor therapy using Salmonella

Combination of vasostatin and cyclophosphamide in the therapy of murine melanoma tumors

A practical algorithm management of patients with benign prostatic hyperplasia